Skip to main content

ORIGINAL RESEARCH article

Front. Public Health
Sec. Public Health Policy
Volume 12 - 2024 | doi: 10.3389/fpubh.2024.1339141

Impact of accelerated review policy on portfolio planning of vaccine companies

Provisionally accepted
Guicui Liu Guicui Liu Zhe Huang Zhe Huang *
  • School of Business Administration, Shenyang Pharmaceutical University, Shenyang, China

The final, formatted version of the article will be published soon.

    Background: With the introduction of the accelerated drug review policy in China, the clinical research and development time and the review and approval time of drugs have been shortened accordingly. Especially under the influence of the COVID-19 pandemic, the vaccine formulations released through the accelerated review policy are springing up, and the question of how the accelerated review policy affects the investment portfolio of vaccine enterprises has also attracted more and more attention. Aims and Methods: The article uses mixed-integer linear programming to develop a new model on portfolio planning for vaccine companies based on the accelerated review policy context. The model is constructed using the Gurobi extension class of .NET, and the investment decision is made and simulated by the Gurobi solver to investigate the portfolio planning decision of a vaccine company maximising the net present value of its vaccine production portfolio with the increase of available capital over a 20-year time horizon. Results: The NPV under the accelerated review policy is significantly higher than the net present value under the standard review policy when the available capital exceeds RMB 900 million. And the difference between the two of them peaks at RMB 1.87 billion when the available capital is RMB 1.9 billion; break-even occurs about 1.3 years earlier in the accelerated review policy than in the standard review; and when the available capital is the same, firms in the accelerated review policy choose to produce four products earlier and make the decision to invest in facility construction earlier; scenarios in the accelerated review policy are not as sensitive to changes in model parameters as they are in the standard review.The accelerated review policy is effective in providing incentives for commercialisation.The results of this study will provide an effective reference for vaccine companies to make scientific portfolio planning under the accelerated review policy.

    Keywords: Mixed-integer linear programming, Accelerated review, Capacity planning, vaccine companies, optimization

    Received: 15 Nov 2023; Accepted: 11 Nov 2024.

    Copyright: © 2024 Liu and Huang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Zhe Huang, School of Business Administration, Shenyang Pharmaceutical University, Shenyang, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.